ReachX logo

COVID-19 - Biopharma’s agility put at test

Research

Publication Date: 25 Mar 2020 - By Scitaris G. By Scitaris G.
Actionable
Differentiated

Thematic Multi Asset Global Pharmaceuticals Biotechnology

Scitaris, a leading biotech and pharma consultancy, is providing a perspective on the biological characteristics of the virus, including:

- implications on its transmission and potential ends to the pandemic

- focusing the race of the biopharma industry to finding a cure

- considerations for investors in the space

Scitaris Covid -19

Source: Scitaris

Pages: 6

Released: 25 Mar 2020

Download Report

The Author

Scitaris G.

Healthcare, Pharmaceuticals, Biotechnology

Connect

 

Most read